Latest Breaking News On - Hussam shaheen - Page 1 : comparemela.com

WorldFish and Norway Spearhead Cutting-Edge Solar Powered Aquaponics Solution

In a ground-breaking move towards a sustainable integrated agriculture-aquaculture- (IAA) system in Egypt, WorldFish has established a solar station to power a demonstration aquaponics greenhouse a

As suwaysAl qahirahNile deltaEgypt generalHussam shaheenAhmed nasr allahMohamed fathiFaculty of fish resources suez universityRenewable energy in aquaculture ceHm groupRoyal norwegian embassyCentral laboratory for aquaculture researchResearch assistant at worldfishDevelopment agencyRenewable energyCountry director

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation

/PRNewswire/ Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody.

United statesJacob milliganEric mcintyreJoana ministroDeanna nguyenBrandy spencerDaniel riosJoshua friedmanHussam shaheenEric zhuRita vazSpyre therapeutics incPrnewswire spyre therapeutics incCompany or spyreParagon therapeutics incClinical development of spyre

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAlex strausNoel kurdiCarl dambkowskiEric zhuHussam shaheenDan budwickStrategic communicationsApogee therapeutics incExchange commissionEuropean academy of dermatologyParagon therapeutics incApogee therapeuticsParagon therapeuticsChief medical officer

Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders

Oversubscribed $149M Series B financing co-led by new investors Deep Track Capital and RTW Investments, LP adds to Series A investment from founding investors.

New zealand generalNew zealandSan franciscoUnited statesHussam shaheenMichael hendersonDunn crutcherPerceptive xontogeny ventures fundDrug administrationFidelity management research companyApogee therapeuticsDeep track capitalVenrock healthcare capital partnersParagon therapeuticsChief executive officerChief executive officer michael henderson